Gastrointestinal Cancer

Long-term survivors of wild-type KRAS colorectal cancer tumors had significantly improved survival with regular use of nonsteroidal anti-inflammatory drugs.

Perioperative chemotherapy with a docetaxel-based triplet should be considered the new standard of care for resectable gastric or GEJ adenocarcinoma.

Lenvatinib demonstrated noninferiority to sorafenib with regard to overall survival in patients with previously untreated, unresectable hepatocellular carcinoma.

Adding PEGPH20 to nab-paclitaxel and gemcitabine improved progression-free survival in patients with untreated, metastatic pancreatic ductal adenocarcinoma.

In this article we will discuss the definitions of resectability, describe the current diagnostic tests for pancreatic cancer, and review strategies for maximizing treatment outcomes in patients with resectable pancreatic cancer.

This video highlights results of the SUNSHINE study, which found that high-dose vitamin D added to standard treatment slowed disease progression in newly diagnosed metastatic colorectal cancer.

This video reviews the use of endoscopic therapy for the management of Barrett esophagus and early esophageal cancer.

This video highlights the evolution of stereotactic body radiation therapy in the treatment of pancreatic cancer.

This video examines the treatment of patients with low-lying rectal cancer and explores options such as neoadjuvant chemoradiotherapy, which could improve the efficacy of surgery.

Patients with stage III colon cancer who maintained a healthy lifestyle had a reduced risk for death and a trend for a lower chance of recurrence.

Attending at least one surveillance visit with colonoscopy benefited most patients diagnosed with intermediate-risk adenomas, according to the results of a retrospective study.

The addition of adjuvant oral chemotherapy with capecitabine extended the overall survival of patients with biliary cancers by a median of 15 months, according to the results of the BILCAP study.

In this review, we address specific issues pertaining to AYA patients with colorectal cancer, including evaluation for hereditary colorectal cancer syndromes, clinicopathologic and biologic features unique to AYA patients with colorectal cancer, treatment outcomes, and survivorship.

This video reviews the use of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery in colorectal cancer with peritoneal carcinomatosis.

Nurse practitioners play a central role in helping patients with esophageal cancer understand and manage their disease and treatment complications.

This video discusses the use of intensity-modulated radiation therapy and whether it should be the new standard for treating patients with esophageal cancer.

This video reviews the advantages and disadvantages of IMRT and proton therapy for the treatment of esophageal cancer.

The FDA has approved regorafenib (Stivarga) for the second-line treatment of hepatocellular carcinoma (HCC) for patients who have previously received sorafenib.

A delay of 10 months or longer between a positive fecal immunochemical test and a follow-up colonoscopy was associated with a higher risk of colorectal cancer.

ASCO updated a 2016 guideline regarding resected pancreatic cancer to include treatment with adjuvant chemotherapy with gemcitabine and capecitabine.

Interim data from CheckMate 040 showed that nivolumab produces durable responses with promising long-term survival rates in patients with advanced, unresectable hepatocellular carcinoma.

Dual HER2 blockade with trastuzumab and lapatinib yielded good response rates in HER2-amplified, RAS wild type, treatment-refractory metastatic colorectal cancer patients, according to results of the HERACLES study.

Aspirin had a greater effect on colorectal cancer survival in patients with low-level CD274 (PD-L1) expression in their tumors, according to the results of a study.

Recent improvements in our understanding of the biology of colorectal cancer have led to the identification of several important prognostic and predictive markers of disease-associated risk and treatment response for the individual patient.

This video reviews first- and second-line treatment options for patients with carcinoma of the gastroesophageal junction.